Drug intelligence / Profile preview

EBL-1463

Development stage: Preclinical
Lead developer: Tamrisa
Modality: Small Molecules
Administration: Intravenous

Overview

EBL-1463 is an intravenous, first-in-class antibacterial from the dabocin family, a novel group of non-beta-lactam diazabicyclooctane derivatives that inhibit penicillin-binding proteins (PBPs) to block bacterial cell-wall synthesis and kill Gram-negative pathogens, including carbapenem-resistant Enterobacterales.[4][5][8][10] Developed initially by Mutabilis and now advanced by Tamrisa with support from initiatives such as ENABLE and CARB-X, EBL-1463 is designed to retain potent PBP-mediated bactericidal activity while exhibiting exceptional stability to class A, B, C, and D beta-lactamases, targeting serious multidrug-resistant infections for which current treatment options are limited.[4][5][8][9][10]

Other names: dabocin EBL-1463

Targets

PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on EBL-1463.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EBL-1463.

Explore the full profile